Pages that link to "Q38840275"
Jump to navigation
Jump to search
The following pages link to The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis (Q38840275):
Displayed 9 items.
- T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab (Q33865748) (← links)
- A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease (Q38373177) (← links)
- Brodalumab for the treatment of psoriasis (Q38975719) (← links)
- Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis (Q39275772) (← links)
- Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy (Q39458219) (← links)
- Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia (Q50047383) (← links)
- Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases (Q57166451) (← links)
- Association of genetic polymorphism of interleukin-17A & interleukin-17F with susceptibility of psoriasis. (Q64884183) (← links)
- A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models (Q89823404) (← links)